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Cite This: Anal. Chem. 2020, 92, 13767−13775 Read Online
ACCESS Metrics & More Article Recommendations *sı Supporting Information
ABSTRACT: The exposome, defined as the cumulative measure of external
exposures and associated biological responses throughout the lifespan, has emerged
in recent years as a cornerstone in biomedical sciences. Metabolomics stands out
here as one of the most powerful tools for investigating the interplay between the
genetic background, exogenous, and endogenous factors within human health.
However, to address the complexity of the exposome, novel methods are needed to
characterize the human metabolome. In this work, we have optimized and validated
a multianalyte metabolomics platform for large-scale quantitative exposome research
in plasma and urine samples, based on the use of simple extraction methods and
high-throughput metabolomic fingerprinting. The methodology enables, for the first
time, the simultaneous characterization of the endogenous metabolome, food-
related metabolites, pharmaceuticals, household chemicals, environmental pollu-
tants, and microbiota derivatives, comprising more than 1000 metabolites in total.
This comprehensive and quantitative investigation of the exposome is achieved in
short run times, through simple extraction methods requiring small-sample volumes,
and using integrated quality control procedures for ensuring data quality. This
metabolomics approach was satisfactorily validated in terms of linearity, recovery,
matrix effects, specificity, limits of quantification, intraday and interday precision, and carryover. Furthermore, the clinical potential
of the methodology was demonstrated in a dietary intervention trial as a case study. In summary, this study describes the
optimization, validation, and application of a multimetabolite platform for comprehensive and quantitative metabolomics-based
exposome research with great utility in large-scale epidemiological studies.
Over the past few years, increasing evidence hasdemonstrated that environmental factors have more
impact on health status than originally thought, beyond the
well-recognized role of the intrinsic genome.1 The “exposome”
has emerged here as a novel research paradigm in biomedical
sciences that could be defined as the totality of external
exposures (e.g., diet, medication, pollution) and associated
biological responses (i.e., endogenous processes) throughout
the lifespan.2,3 Considering this complex interplay among
multiple biological and lifestyle conditions, metabolomics is
currently one of the most powerful technologies for holistically
deciphering the molecular mechanisms driving the final
phenotype, given that metabolites are direct indicators of the
functional status of biological systems. In recent years, the use
of metabolomics has exponentially increased in nutritional,
pharmacological, and toxicological research.4,5 Other lifestyle
habits with deep impact on the human metabolome and health
status include smoking, the consumption of alcohol and illicit
drugs, and physical activity.6,7 Within this tangled metabolic
framework, the prominent role of gut microbiota in host health
should also be noted, since it is involved in the absorption of
nutrients, the metabolism of xenobiotics, the synthesis of
biologically active metabolites, and other functions.8,9
The vast chemical complexity and dynamic range of the
exposomebeing endogenous and food-derived metabolites
normally found in the picomolar to millimolar (pM−mM)
concentration range, while pollutants can be present at levels 3
orders of magnitude lower10make the application of high-
throughput and versatile techniques mandatory. Traditional
approaches based on targeted biomonitoring of specific
biomarkers are inherently biased to the predefined set of
analytes, usually being time-consuming and requiring large
sample volumes.11 On the other hand, nontargeted metab-
olomics allows the coverage to be expanded to thousands of
metabolites, considering not only exogenous compounds but
also endogenous metabolites altered by the exposure, thereby
providing a simultaneous overview on both external factors and
the associated phenotypic variations.12,13 Nonetheless, non-
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targeted approaches also present critical limitations: (i) lower
sensitivity than targeted methods, which impedes the detection
of minor metabolites; (ii) lower reproducibility due to the
semiquantitative nature of the measurement; and (iii) the
limited number of compounds characterized in metabolomics
databases, which hinders their annotation and subsequent
biological interpretation.11,14 Accordingly, in recent years,
more and more authors have emphasized the need to move to
large-scale quantitative metabolomics for comprehensive
exposome research, which would enable cross-cohort and
interlaboratory comparisons, the pooling of data, and defining
“quantitative reference metabolomes”.15−17
The aim of the present work was to accomplish, for the first
time, the development of a high-throughput metabolomics
method to capture the metabolic complexity of the human
exposome in a comprehensive and quantitative fashion. To this
end, we considered endogenous metabolites involved in central
pathways, food-related metabolites, commonly consumed
drugs, chemicals coming from personal care products, plastic
additives and environmental pollution, biomarkers of other
lifestyle habits (e.g., smoking, alcohol consumption), and
metabolites related to microbiota detoxification processes, food
metabolism, and host health. To facilitate its implementation
in large-scale epidemiological studies, we optimized simple,
efficient, and small-sample consuming extraction methods for
both urine and plasma samples, combined with a high-
throughput metabolomics platform for comprehensive and
quantitative characterization of the exposome in short run
times. This metabolomics approach was subsequently applied
to samples collected in a long-term intervention trial with olive
oil as a case study to perform a clinical validation of the
methodology.
■ EXPERIMENTAL SECTION
Chemicals and Standards. Acetonitrile, water, water with
0.1% formic acid (v/v), and formic acid (Optima, LC/MS
grade) were purchased from Fisher Scientific (Leicestershire,
U.K.), while ammonium formate (MS-grade) was supplied by
Sigma−Aldrich (Steinheim, Germany). Standards of analytical
purity for 639 metabolites and 14 internal standards (ISs) were
obtained from various commercial sources, while 37 food
metabolites were synthesized in-house, as detailed elsewhere
(see Table S1 in the Supporting Information).18,19 Individual
stock solutions for all 690 compounds were prepared at
concentrations of 10 000 mg/L for endogenous metabolites or
1000 mg/L for exogenous ones and ISs, using the solvent
recommended by the supplier and/or literature, and stored at
−80 °C. From these stock solutions, three multimetabolite
working solutions were prepared at 50 mg/L in water:-
acetonitrile (80:20 (v/v)), and these were employed to build
the calibration curves by serial dilution and to prepare spiked
urine/plasma samples for validation purposes. We also
prepared a fourth working solution by combining a set of 13
ISs, depicting the broad chemical diversity of the metabolite
classes assayed (see Table S1). To optimize the extraction
conditions and method validation, we employed anonymized
pooled samples of urine and plasma collected in previous
studies from healthy volunteers after 1 week of a low-
polyphenol diet.20
Sample Preparation. Urine samples were first centrifuged
at 10 000g for 10 min at 4 °C, and then the supernatants (20
μL) were diluted 5-fold with 80 μL of ultrapure water
containing 0.1% formic acid (v/v) and 125 μg/L of the IS set
previously described. Plasma samples (100 μL) were first
spiked with 10 μL of 1 mg/L indoleacetic acid-d2 in water (IS
to monitor the extraction efficiency). Samples were sub-
sequently mixed with 500 μL of cold acetonitrile (−20 °C)
containing 1.5 M formic acid and 10 mM ammonium formate
in a Sirocco Protein Precipitation plate (Waters, Milford, MA,
USA), vortexed for 1 min, and kept at −20 °C for 10 min to
promote protein precipitation (PPT). Then, a Waters Positive
Pressure-96 Processor was employed to collect the extracts in
96-well collection plates, which were taken to dryness using a
MaxiVac β vacuum concentrator (Daejeon, South Korea).
Finally, samples were reconstituted in 100 μL of water:-
acetonitrile (80:20, v/v) containing 0.1% formic acid (v/v)
and 100 μg/L of the 13-IS set previously described and
centrifuged at 1000g for 5 min; clean extracts then were
transferred to 96-well plates for further analysis.
Multianalyte Targeted Metabolomics Analysis. Anal-
yses were performed on a 1290 Infinity UHPLC system
(Agilent, Santa Clara, CA, USA) coupled to a QTRAP 6500
mass spectrometer equipped with Ion Drive Turbo V ion
source (Sciex, Framingham, MA, USA). Chromatographic
separation was performed on a Luna Omega Polar C18
column, 100 mm × 2.1 mm (i.d. 1.6 μm), equipped with a fully
porous polar C18 security guard cartridge (Phenomenex,
Torrance, CA, USA). Mobile phases employed under positive-
ion mode detection consisted of water (A) and acetonitrile
(B), both containing 0.5% formic acid, by applying the
following gradient program: 0−5 min, 5%−50% B; 5−8 min,
50%−100% B; 8−10 min, 100% B; 10−10.1 min, 100%−5% B;
10.1−12 min, 5% B. In the negative-ion mode, water
containing 0.1% formic acid and 10 mM ammonium formate
(A) and acetonitrile (B) were delivered as follows: 0−8 min,
5%−20% B; 8−10 min, 20%−100% B; 10−12 min, 100% B;
12−12.1 min, 100%−5% B; 12.1−14 min, 5% B. Other
chromatographic conditions were as follows: column temper-
ature, 40 °C; autosampler temperature, 4 °C; injection volume,
2 μL; and flow rate, 0.5 mL/min. Mass spectrometry detection
was performed under positive and negative ionization in
separate runs, by using the scheduled multiple reaction
monitoring (sMRM) mode. General MS parameters were as
follows: ion spray voltage, +4500/−3500 V; source temper-
ature, 600 °C; curtain gas, 30 psi; ion source gas 1 and gas 2,
50 psi each; collision-activated dissociation gas, 3 psi; entrance
potential, ±10 V; and target scan time, 0.05 s. The MRM
transitions were optimized by infusing standard solutions
dissolved in mobile phase (proportion A:B 1:1 v/v, 500 μg/L)
into the mass spectrometer using a syringe pump at 5 μL/min
flow rate (MSMS data are available in MetaboLights, study
identifier: MTBLS1906). Complementarily, other metabolites
for which authentic standards are not currently available were
identified in real urine and plasma samples by means of
product ion scan analysis (MS2 and MS3) using the predicted
nominal masses of these metabolites (level II identification
according to the Metabolomics Standard Initiative), and their
fragmentation conditions were experimentally optimized (see
the subsection entitled “Method Optimization”). The semi-
quantification of these metabolites without standard was
achieved by using the calibration curves of structurally similar
metabolites, such as structural isomers (e.g., quantification of
2-methylbutyryl-L-carnitine with the calibration curve of
valeryl-L-carnitine) or the corresponding aglycone for phase
II metabolites (e.g., quantification of phloretin glucuronide
with the calibration curve of phloretin). Optimized MRM
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transitions, declustering potentials, collision energies, cell exit
potentials, retention times and RT windows are listed in Table
S2 in the Supporting Information. Analyst 1.6.2 and Sciex OS-
Q software (ABSciex, Framingham, MA, USA) were used for
data acquisition and processing, respectively.
Analytical Validation. The optimized metabolomics
approach was validated according to the requirements defined
by the Center for Drug Evaluation and Research from the
United States Food and Drug Administration (FDA) for
bioanalytical method validation.21 The linearity was assessed
by analyzing calibration curves, prepared in both solvent and
blank urine/plasma, at 12 concentration levels within the range
of 0.1−10 000 μg/L. The extraction recovery was determined
by spiking blank urine/plasma samples at three concentration
levels (1, 100, 1000 μg/L), which were analyzed in triplicate.
Recovery percentages were calculated considering the
endogenous levels found in blank samples using the following
formula:
recovery (%)
final concentration initial concentration
added concentration
100= − ×
To assess matrix effects (ME), we compared the MS response
of standards dissolved in solvent and extracted urine/plasma at
the same concentration level (1, 100, 1000 μg/L). Method
specificity was evaluated by testing the absence of interferences
in blank solvents and extraction blanks, and by computing the
retention time variability in solvent, blank urine/plasma and
spiked urine/plasma along a 3-day analysis sequence. The
limits of quantification (LOQ) were estimated in spiked urine/
plasma samples as the lowest concentration giving an average
signal-to-noise (S/N) ratio of >10, measurable with an
imprecision of <20%. These values were calculated by
subtracting the analyte response observed in nonspiked
samples. Intraday and interday precisions were evaluated by
analyzing spiked urine/plasma samples at three concentration
levels (1, 100, 1000 μg/L) five times within the same day, as
well as on three consecutive days, respectively. Carryover was
Figure 1. Graphical summary of the analytical coverage of the multimetabolite exposome-based metabolomics approach developed.
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tested by analyzing blank water after injecting urine/plasma
spiked at a concentration of 1000 μg/L.
Application to a Dietary Intervention Study. For
clinical validation of the metabolomics method optimized, we
analyzed urine and plasma samples collected in a long-term
dietary intervention. The study consisted of a controlled
crossover trial with olive oil (80 g/day) lasting for one month
in 10 healthy volunteers (6 males, 4 females, 40.4 ± 4.1 y),
following the general study design recommendations in
exposure/nutritional assessment research.4 First-morning
urine and fasting plasma samples were collected at baseline
and at the end of the intervention period, and these were
stored at −80 °C until analysis. Urinary creatinine levels were
analyzed using a Jaffe reaction-based kit (Siemens Healthi-
neers, Erlangen, Germany) to normalize metabolomics data.
The study was performed in accordance with the principles
contained in the Declaration of Helsinki. The Bioethical
Committee of the Hospital Virgen de la Victoria (Maĺaga,
Spain) approved the study protocol, and all the participants
provided written informed consent. The study was registered
under ClinicalTrials.gov as NCT03101436.
Quality Control Assessment. Data quality control (QC)
assessment was accomplished through a standardized protocol
developed in-house, comprising the following steps: (i) data
preprocessing, (ii) detection of sample outliers, (iii) sample
quality assessment, and (iv) method reproducibility assess-
ment. Data preprocessing included the removal of metabolites
with more than 20% missing values in all the study groups and
the imputation of the remaining missing values by using the
KNN algorithm,22 and subsequent data normalization by
applying log transformation and Pareto scaling. The distances
to the group centroid then were computed based on Euclidean
distances to detect outliers in the data matrix. After outlier
removal, if needed, metabolites known to be influenced by
preanalytical factors were employed to check the absence of
abnormal values (±1.5 × IQR), which could be indicative of
improper handling/storage of blood (e.g., lactate) and/or urine
(e.g., succinate) samples.23,24 Finally, reproducibility was
evaluated by calculating the coefficients of variation for
concentrations, retention times, and peak widths for ISs
added to each sample.
Statistical Analysis. The metabolomics datasets obtained
after analyzing urine and plasma samples from the clinical
validation study were subjected to t-test statistical analysis to
look for altered metabolites because of the intervention with
olive oil. Fold changes were calculated using the following
formula:
fold change (%)






Method Optimization. We compared various extraction
methods for the comprehensive characterization of the human
exposome, both in urine and plasma samples, considering more
than 1000 metabolites, as illustrated in Figure 1. Simple
dilution and reversed solid-phase extraction (SPE) (Oasis
HLB) were tested for urine treatment, whereas plasma
extraction was accomplished by means of protein precipitation
(in tubes and in 96-well filtration plates), reversed solid-phase
extraction (Oasis HLB), and hybrid protein precipitation with
simultaneous SPE-mediated phospholipid removal (Ostro), as
reported in our previously published studies focused on
investigating the human food metabolome in urine18 and
plasma19 samples.
For urine, simple dilution provided the best performance in
terms of coverage, enabling the simultaneous analysis of the
wide range of metabolites assayed. To minimize matrix effects
and obtain maximum sensitivity, 5-fold dilution was found to
be the optimum procedure, since lower dilution factors
provoked increased ion suppression, whereas minor metabo-
lites became undetectable by applying higher dilutions. On the
other hand, an in-plate PPT-based protocol was optimized for
plasma analysis. The best extraction efficiency was obtained by
using acetonitrile containing 1.5 M formic acid and 10 mM
ammonium formate as the precipitation solvent, which allows
interactions between proteins and metabolites to be reduced,
especially for low-polarity ones (e.g., polyphenols, lipids).19
Noteworthy, similar extraction performance was observed
using plasma volumes in the range of 20−100 μL, but with an
inherent loss of sensitivity with lower volumes.
The chromatographic method was optimized to achieve
maximum resolution and sensitivity for all the metabolites
listed in Table S2, especially considering the presence of
isomeric compounds, following a modification of the method-
ology described elsewhere.18,19 For this purpose, two different
mobile phase sets and gradient elution programs were
employed under positive and negative ionization modes to
manage the chemical complexity of the human exposome. The
use of formic acid and ammonium formate as mobile phase
additives and an aprotic organic solvent (i.e., acetonitrile) in
the negative ion mode provided satisfactory chromatographic
resolution, reducing peak tailing for sulfate (e.g., sulfated
steroids, phase II phenolics) and phosphate (e.g., organo-
phosphate pesticides) metabolites, which consequently re-
sulted in increased S/N ratios and, therefore, improved
analytical sensitivity. In contrast, chromatographic separation
under positive polarity was performed by using more acidic
mobile phases, which significantly enhanced electrospray
ionization and provided better peak resolution for some
specific metabolite classes (e.g., anthocyanins).25
For MS detection, the MRM transitions were optimized by
infusing standard solutions into the mass spectrometer for 676
metabolites (+14 ISs). Furthermore, 352 additional metabo-
lites were also included to expand the method coverage,
considering other biologically important metabolites not
commercially available (e.g., individual lipid species, exogenous
phase II derivatives). To this end, urine/plasma samples were
analyzed under the product ion scan (MS2) mode by using
predicted nominal masses of these metabolites, looking for
expected fragments (e.g., 85 Da for acylcarnitines, 184 Da for
lysophosphatidylcholines) or neutral losses (e.g., 176 Da for
glucuronides, 80 Da for sulfates). If needed, MS3 fragmenta-
tion experiments were conducted to confirm the annotation.
Compound-dependent parameters for these metabolites were
experimentally optimized to achieve the highest sensitivity (see
Table S2). Altogether, the metabolomics platform developed
enables the simultaneous quantitation of 1019 metabolites in
very short run times (12 min +14 min in the positive- and
negative-ion modes, respectively). Despite the huge number of
transitions monitored, the minimum number of data points
across chromatographic peaks was 15, which ensures good
accuracy and reproducibility.
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Figure 2. Column plots with standard deviation bars showing the distribution of recovery rates (for plasma (panel (A) and urine (panel (B)),
matrix effects (for plasma (panel (C) and urine (panel (D)), logarithmic transformed limits of quantification (for plasma (panel (E) and urine
(panel (F)), intraday precisions (for plasma (panel (G) and urine (panel (H)), and interday precisions (for plasma (panel (I) and urine (panel (J))
for all the validated metabolites (n = 667) in plasma and urine.
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Analytical Validation. A conscientious analytical valida-
tion was performed according to the FDA guidelines, as
summarized in Figure 2 (detailed information is given in
Tables S3 and S4 in the Supporting Information). Calibration
curves, prepared both in solvent and biological matrix, showed
high linear responses over 3−5 orders of magnitude within the
concentration range of 0.1−10 000 μg/L, with correlation
coefficient (R2) values of >0.99 for all the metabolites.
Satisfactory recovery rates (70%−125%) were obtained for
most of the validated metabolites (85.6% and 95.8% of the
total in plasma and urine, respectively) with negligible matrix
effects (MEs) (see Figures S1 and S2 in the Supporting
Information), which supports the possibility of using
calibration curves prepared in solvent instead of matrix-
matched calibrations to simplify the analytical workflow. More-
pronounced ion suppression (ME 50%−70%) was observed
for some polar metabolites detected in the void volume (e.g.,
polyamines) and flavonoid aglycones chromatographically
coeluting with highly abundant phospholipids (only in
plasma). Only for some sugar derivatives, the extent of ion
suppression impeded their analysis in plasma samples (ME <
50%). Moreover, slightly lower recovery rates were found for
the PPT-based extraction of some anthocyanins and
isoflavones from plasma, which is consistent with previous
findings.19 To assess the method specificity, the conventional
procedure based on proving the lack of response in blank
matrix was not suitable due to the endogenous presence of
many of the metabolites assayed. As an alternative approach,
we checked the absence of signal in blank solvents and
extraction blanks, and we computed the retention time
variability as a metric of the method’s ability to differentiate
a metabolite in the presence of potential interferences (i.e.,
closely coeluting structural isomers, e.g., leucine and
isoleucine). Blank solvents and extraction blanks only showed
appreciable levels of some fatty acids, phthalates, and bisphenol
A, because of their ubiquitous presence in plastic ware (these
blank levels should therefore be subtracted from concen-
trations found in real samples). On the other hand, retention
time variability was <3 s along a three-day analytical sequence
for all the measured metabolites, both in solvent and biological
matrix, thereby demonstrating the stability of the metabolo-
mics platform and, consequently, its specificity to differentiate
potential interferences. However, note that some isomeric
metabolites were unresolved, because of the inherent
limitations of reversed-phase chromatography (those marked
with the symbol “§” in Table S2). The LOQs calculated for
plasma and urine were very similar and indicated satisfactory
sensitivity to detect most of the metabolites in real samples,
according to the normal concentration ranges displayed in the
Human Metabolome Database (HMDB) (IDs are listed in
Table S2). These LOQs were lower than 50 μg/L for ∼75% of
the metabolites monitored (Figure 2), with 10% of the
metabolites being quantifiable at sub-ppb levels. Relative
standard deviations for intraday and interday precision were
0.1%−16.4% and 0.3%−18.9% for plasma, whereas, for urine,
they varied over the ranges of 0.1%−16.1% and 1.5%−19.6%,
respectively, below the 20% acceptance limit established by the
FDA.21 The analysis of blank solvent after injecting urine/
plasma samples spiked at 1000 μg/L evidenced appreciable
carryover for some metabolite classes (e.g., acylcarnitines,
pharmaceuticals). However, the signal detected in blanks was
<20% of the LOQ for these metabolites, within the acceptable
range.
Application to a Dietary Intervention Study. The
previously optimized and validated metabolomics platform was
applied to urine and plasma samples collected from a dietary
intervention study with olive oil to check its clinical potential.
Most of the endogenous metabolites monitored (>90%) were
successfully quantified in >80% of the samples analyzed,
thereby demonstrating satisfactory method sensitivity. Among
food-related metabolites, phenolic acids, methylxanthines, and
other microbiota derivatives (e.g., enterolignans, hydroxyphen-
yl-valerolactones) were also regularly detected in urine and, to
a lesser extent, in plasma samples. Similarly, other chemicals
ubiquitously present in personal care products (e.g., parabens,
phthalates, benzophenones) could also be found in most of the
samples analyzed. However, the detection rate of other
exogenous metabolites was much lower (e.g., flavonoids,
drugs), thus indicating their specificity as exposure biomarkers.
These metabolomics data were first subjected to QC
assessment to check the absence of analytical and preanalytical
outliers, and to validate the analytical performance. No outlier
was detected, and the coefficients of variation for the
concentrations, retention times and peak widths for ISs were
below 15%, 1%, and 10%, respectively, both in urine and
plasma. Afterward, t-test analysis was applied to look for
differential metabolites, because of the dietary intervention, as
shown in Table 1.
■ DISCUSSION
This work presents the development of a novel multianalyte
targeted metabolomics platform for large-scale quantitative
exposome research, as illustrated in Figure 1. On the one hand,
Table 1. Differential Metabolites Identified in Urine and
Plasma Samples (t-Test, p < 0.05) Following a 1-Month
Intervention with Olive Oil
metabolite p-value fold change (%)
Urine
hydroxytyrosol 4′-sulfate 0.020787 +1816.9






pyroglutamic acid 0.010146 +21.5
asymmetric dimethylarginine 0.011142 +46.5
trimethylamine 0.011555 +12.6
glutaryl-L-carnitine 0.012186 +27.3
succinic acid 0.013465 +16.9









glycochenodeoxycholic acid 3-glucuronide 0.032348 +178.2
indoleacetic acid 0.036501 +47.6
docosatetraenoic acid 0.044264 +6.8
phenylalanine 0.047083 +16.8
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we considered ∼500 endogenous metabolites covering a broad
range of chemical classes (e.g., amino acids and derivatives,
organic acids, biogenic amines, vitamins, fatty acids,
acylcarnitines, steroids). To build this endometabolome
library, we focused on metabolites involved in central
metabolic pathways according to metabolomics databases
(e.g., HMDB, KEGG), also taking as a reference some
metabolite kits commonly employed in metabolomics research
(e.g., Biocrates MxP Quant 500 kit, IROA MSMLS) and
related literature.26−28 Furthermore, 450 additional metabo-
lites were also monitored to obtain a representative overview of
the food metabolome and other lifestyle habits (e.g., smoking,
alcohol consumption), based on the associations defined in the
Food Biomarker Ontology.29 Besides these food-related
metabolites, the method coverage also comprises other
common xenobiotics,30 including pollutants (e.g., organo-
phosphate pesticides, polycyclic aromatic hydrocarbons,
arsenic metabolites), household chemicals (e.g., parabens,
benzophenones, bisphenols, phthalates, perfluoroalkyl sub-
stances) and commonly consumed drugs (e.g., statins,
analgesics, antibiotics, antidiabetics, antihypertensives, anti-
inflammatories, antidepressants, antihistamines), thereby en-
abling comprehensive exposure assessment. To investigate the
role of microbiota in this complex interplay between external
factors and endogenous processes, we also considered multiple
microbiota-derived metabolites, such as biotransformed food
components (e.g., urolithins, hydroxyphenyl-valerolactones),
aromatic amino acid derivatives (e.g., neurotransmitters,
indoles), short-chain fatty acids, bile acids, vitamins, and
others.
The metabolomics platform developed thus enables the
simultaneous detection of 1,019 metabolites in short run times
(<30 min per sample). Furthermore, extraction methods
optimized are simple, easily automatable (e.g., 96-well based
robotic systems), and employ small sample volumes (<20 μL
urine, 20−100 μL plasma/serum). All this highlights the great
applicability of the methodology in epidemiological research
for dealing with large sample cohorts. Although achieving
optimum analytical performance for all the metabolites under
study at the same time is rather unrealistic, most of them were
satisfactorily validated in terms of linearity, recovery, matrix
effects, specificity, limits of quantification, intraday and
interday precision, and carryover (Figure 2).
A few multimetabolite methods have previously been
described for investigating specific metabolomics compart-
ments, including the endometabolome,26−28 the food metab-
olome,18,19 the pharmaco-metabolome,31 and the toxico-
metabolome.32 However, to the best of our knowledge, the
metabolomics platform optimized in this study represents the
first approach to simultaneously characterize a larger swath of
the exposome, providing much wider coverage in a single
analysis. Furthermore, it is also noteworthy that our method
consisted of multiple biotransformed exogenous metabolites
(e.g., phase II derivatives), which allows the metabolism and
detoxification processes of xenobiotics to be studied, unlike
most of the conventional targeted metabolomics approaches
based on enzymatic hydrolysis. This hydrolysis step is usually
employed to reduce the metabolome complexity and simplify
quantification, but it hinders the simultaneous analysis of
multiple biomarkers, because optimal deconjugation con-
ditions differ, depending on the metabolite class.33,34 This
therefore emphasizes the great potential of the metabolomics
approach developed here to obtain a comprehensive and
realistic overview of the human exposome.
Finally, this methodology was successfully applied in an
intervention trial with olive oil as a case study to demonstrate
its applicability. Statistical analysis of the metabolomics data
set showed a significant increase in urinary levels of
hydroxytyrosol derivatives, validated biomarkers of olive oil
intake.29 On the other hand, the analysis of plasma samples
revealed alterations in several metabolic pathways because of
this intervention, including homeostasis of amino acids, one-
carbon metabolism, and fatty acid oxidation (Table 1). This
therefore demonstrates the complementarity of using both
matrices in biomedical research, with exogenous metabolites
being predominantly detected in urine, whereas blood samples
provide more insights into endogenous processes and the
phenotypic status.
■ CONCLUSIONS
In summary, this work describes, for the first time, the
optimization, validation. and application of a multimetabolite
platform for comprehensive and quantitative metabolomics-
based exposome research, with great utility in numerous
research fields, because of the broad metabolome coverage,
e.g., health research, nutrimetabolomics, toxicometabolomics,
and pharmacometabolomics. The main strengths of this novel
approach are (i) the ability to simultaneously quantify more
than 1000 metabolites, (ii) both in urine and blood samples,
(iii) in short-run times, (iv) by applying simple and
automatable extraction methods, and (v) using small-sample
volumes, which therefore facilitates its implementation in large-
scale epidemiological studies. On the other hand, the most
important limitation of this methodology was the inherent
inability of reversed-phase chromatography to resolve polar
metabolites, which would make the development of orthogonal
complementary approaches (e.g., hydrophilic interaction
chromatography) necessary. Furthermore, the use of high-
throughput extraction methods based on dilution and PPT,
devised to allow for large-scale quantitation of as many
metabolites as possible, might hinder the detection of some
minor exogenous metabolites, which usually require specific
extraction and cleanup procedures. To overcome this hurdle,
solid-phase extraction procedures could be complementarily
applied, as recently reported.18,19 Finally, note that standards
were not available for many of the metabolites assayed. To
partially solve this drawback, we included them in the
multimetabolite MS method after being identified in real
urine/plasma samples, thereby enabling their detection and
semiquantification. We would like to make the point here that
the method presented in this study is not intended to be
definitive, but rather might undergo constant evolution and
improvement with new metabolites.
This large-scale multianalyte targeted approach was tested in
plasma and urine samples collected from a pilot dietary
intervention trial with the aim of assessing the metabolomics
coverage of this methodology in real samples, and exploring its
ability to investigate diet-induced metabolomics alterations as a
case study. In this regard, future studies are needed to assess
the clinical potential of this metabolomics platform in larger
sample cohorts.
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the human diet in the crosstalk between nutrition and health by multi-
targeted metabolomics of food and microbiota-derived metabolites.
Int. J. Obes. 2020, DOI: 10.1038/s41366-020-0628-1.
(20) Rotches-Ribalta, M.; Urpi-Sarda, M.; Llorach, R.; Boto-
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